Clinical Trial Update: 1 Year Open-label Extension to CZOL446H2337 Safety and Efficacy Trial of Zoledronic Acid Twice Yearly in Osteoporotic Children Treated With Glucocorticoids [Phase 3]

View source ↗

Summary

Open-label extension trial update for zoledronic acid given twice yearly in osteoporotic children treated with glucocorticoids; completed phase 3 study with pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis

Drugs mentioned

• Zoledronic acid (Zoledronic acid)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Osteoporosis | Phase 3 | Status: COMPLETED | Results posted: 2019-09-20